IL134382A0 - Thyromimetic antiobesity agents - Google Patents
Thyromimetic antiobesity agentsInfo
- Publication number
- IL134382A0 IL134382A0 IL13438200A IL13438200A IL134382A0 IL 134382 A0 IL134382 A0 IL 134382A0 IL 13438200 A IL13438200 A IL 13438200A IL 13438200 A IL13438200 A IL 13438200A IL 134382 A0 IL134382 A0 IL 134382A0
- Authority
- IL
- Israel
- Prior art keywords
- lower alkyl
- hydrogen
- cycloalkyl
- aryl
- hydroxy
- Prior art date
Links
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 229940125710 antiobesity agent Drugs 0.000 title 1
- 230000000929 thyromimetic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 229940125709 anorectic agent Drugs 0.000 abstract 1
- 239000002830 appetite depressant Substances 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Valve Device For Special Equipments (AREA)
- Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
- Discharging, Photosensitive Material Shape In Electrophotography (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12201599P | 1999-03-01 | 1999-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL134382A0 true IL134382A0 (en) | 2001-04-30 |
Family
ID=22400061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13438200A IL134382A0 (en) | 1999-03-01 | 2000-02-03 | Thyromimetic antiobesity agents |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6344481B1 (xx) |
| EP (1) | EP1036564B1 (xx) |
| JP (1) | JP2000256190A (xx) |
| KR (1) | KR100368354B1 (xx) |
| AT (1) | ATE282410T1 (xx) |
| AU (1) | AU1635300A (xx) |
| CA (1) | CA2299972C (xx) |
| CO (1) | CO5150235A1 (xx) |
| DE (1) | DE60015831T2 (xx) |
| ES (1) | ES2233282T3 (xx) |
| HU (1) | HUP0000921A3 (xx) |
| IL (1) | IL134382A0 (xx) |
| NZ (1) | NZ503122A (xx) |
| PE (1) | PE20001539A1 (xx) |
| ZA (1) | ZA200001000B (xx) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716810B1 (en) * | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
| US6344481B1 (en) * | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
| US20070203225A1 (en) * | 2001-04-03 | 2007-08-30 | Havel Peter J | Method of increasing endogenous adiponectin production and leptin production |
| WO2002081751A2 (en) * | 2001-04-03 | 2002-10-17 | The Regents Of The University Of California | A method of increasing endogenous leptin production |
| US20050261362A1 (en) * | 2004-03-22 | 2005-11-24 | The Regents Of The University Of California | Method of increasing endogenous adiponectin and leptin production |
| CA2478183C (en) * | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US20040077650A1 (en) * | 2002-10-18 | 2004-04-22 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1669350B1 (en) | 2003-09-22 | 2012-02-29 | Msd K.K. | Piperidine derivatives |
| EP1689383B1 (en) * | 2003-11-19 | 2012-10-31 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| US20090028925A1 (en) * | 2005-05-26 | 2009-01-29 | Erion Mark D | Novel Phosphinic Acid-Containing Thyromimetics |
| CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| AU2006253312B2 (en) | 2005-05-30 | 2011-08-18 | Msd K.K. | Novel piperidine derivative |
| AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
| JPWO2007024004A1 (ja) | 2005-08-24 | 2009-03-05 | 萬有製薬株式会社 | フェニルピリドン誘導体 |
| EP1939194A4 (en) | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| EP2332526A3 (en) | 2005-10-21 | 2011-10-12 | Novartis AG | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
| JP4371164B2 (ja) | 2005-11-10 | 2009-11-25 | 萬有製薬株式会社 | アザ置換スピロ誘導体 |
| WO2007132475A1 (en) * | 2006-05-15 | 2007-11-22 | Cadila Healthcare Limited | Selective tr-beta 1 agonist |
| CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
| WO2008038692A1 (fr) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
| WO2008120653A1 (ja) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | インドールジオン誘導体 |
| AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009110510A1 (ja) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | アルキルアミノピリジン誘導体 |
| US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2727914A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diaryl ketoxime derivative technical field |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
| EP2346814A2 (en) | 2008-10-27 | 2011-07-27 | Cadila Healthcare Limited | Thyroid receptor ligands |
| EP2362731B1 (en) | 2008-10-31 | 2016-04-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010086878A2 (en) | 2009-01-09 | 2010-08-05 | Cadila Healthcare Limited | Thyroid receptor modulators |
| CN102459185B (zh) | 2009-04-20 | 2015-06-03 | 田边三菱制药株式会社 | 新型甲状腺激素β受体激动剂 |
| WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9401828B2 (en) | 2010-05-20 | 2016-07-26 | Kandou Labs, S.A. | Methods and systems for low-power and pin-efficient communications with superposition signaling codes |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| MX357121B (es) | 2011-03-01 | 2018-06-27 | Synergy Pharmaceuticals Inc Star | Proceso de preparacion de agonistas c de guanilato ciclasa. |
| JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病性三環式化合物 |
| CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
| BR112019007543A2 (pt) | 2016-10-14 | 2019-07-02 | Tes Pharma S R L | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase |
| MX2019005730A (es) | 2016-11-21 | 2019-10-21 | Viking Therapeutics Inc | Metodo para tratar enfermedad de almacenamiento de glucogeno. |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| CN110996966A (zh) | 2017-06-05 | 2020-04-10 | 维京治疗公司 | 用于治疗纤维化的组合物 |
| CN111094554A (zh) | 2017-09-14 | 2020-05-01 | 国立研究开发法人理化学研究所 | 视网膜组织的制备方法 |
| MX2020009843A (es) | 2018-03-22 | 2020-12-11 | Viking Therapeutics Inc | Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto. |
| AU2019385644A1 (en) | 2018-11-20 | 2021-06-03 | Tes Pharma S.R.L. | Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase |
| JPWO2020184720A1 (xx) | 2019-03-13 | 2020-09-17 | ||
| US20230313133A1 (en) | 2020-09-11 | 2023-10-05 | Riken | Complex Containing Neural Retina-Containing Cell Aggregates and Matrix, and Method for Manufacturing Same |
| EP4201428A1 (en) | 2020-09-11 | 2023-06-28 | Sumitomo Pharma Co., Ltd. | Medium for tissue for transplantation |
| AU2022390766A1 (en) | 2021-11-19 | 2024-06-20 | Riken | Production method for sheet-like retinal tissue |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5315739B2 (xx) * | 1973-10-30 | 1978-05-26 | ||
| JPS50124993A (xx) * | 1974-03-20 | 1975-10-01 | ||
| JPS5937018B2 (ja) * | 1978-06-16 | 1984-09-07 | 株式会社トクヤマ | 難燃化ポリプロピレン組成物 |
| ZA824382B (en) | 1981-07-07 | 1984-02-29 | Wyeth John & Brother Ltd | Anti-obesity agents |
| GB8501372D0 (en) * | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
| GB8519154D0 (en) | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
| GB8714901D0 (en) | 1986-07-23 | 1987-07-29 | Ici Plc | Amide derivatives |
| GB8801306D0 (en) | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
| DE69314718T2 (de) | 1992-07-21 | 1998-02-26 | Ciba Geigy Ag | Oxamidsäure-Derivate als hypocholesterämische Mittel |
| JPH0834976A (ja) * | 1994-07-25 | 1996-02-06 | Asahi Denka Kogyo Kk | 潜熱利用型蓄熱材 |
| US6068976A (en) * | 1995-03-20 | 2000-05-30 | Ligand Pharmaceuticals Incorporated | Modulators of ob gene and screening methods therefor |
| EP0920864A1 (en) * | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
| US6344481B1 (en) * | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
| SK12102001A3 (sk) * | 1999-03-01 | 2002-10-08 | Pfizer Products Inc. | Oxámové kyseliny a ich deriváty ako ligandy tyreoidného receptora |
-
2000
- 2000-01-20 US US09/488,110 patent/US6344481B1/en not_active Expired - Fee Related
- 2000-02-03 IL IL13438200A patent/IL134382A0/xx unknown
- 2000-02-03 DE DE60015831T patent/DE60015831T2/de not_active Expired - Fee Related
- 2000-02-03 EP EP00300830A patent/EP1036564B1/en not_active Expired - Lifetime
- 2000-02-03 AT AT00300830T patent/ATE282410T1/de not_active IP Right Cessation
- 2000-02-03 ES ES00300830T patent/ES2233282T3/es not_active Expired - Lifetime
- 2000-02-11 AU AU16353/00A patent/AU1635300A/en not_active Abandoned
- 2000-02-25 JP JP2000049507A patent/JP2000256190A/ja active Pending
- 2000-02-28 PE PE2000000162A patent/PE20001539A1/es not_active Application Discontinuation
- 2000-02-28 KR KR10-2000-0009860A patent/KR100368354B1/ko not_active IP Right Cessation
- 2000-02-28 HU HU0000921A patent/HUP0000921A3/hu unknown
- 2000-02-29 NZ NZ503122A patent/NZ503122A/en unknown
- 2000-02-29 ZA ZA200001000A patent/ZA200001000B/xx unknown
- 2000-02-29 CA CA002299972A patent/CA2299972C/en not_active Expired - Fee Related
- 2000-03-01 CO CO00014834A patent/CO5150235A1/es unknown
-
2001
- 2001-10-16 US US09/978,980 patent/US6555578B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200001000B (en) | 2001-08-29 |
| EP1036564A1 (en) | 2000-09-20 |
| KR20010006712A (ko) | 2001-01-26 |
| DE60015831T2 (de) | 2005-12-15 |
| PE20001539A1 (es) | 2001-01-08 |
| NZ503122A (en) | 2001-11-30 |
| CO5150235A1 (es) | 2002-04-29 |
| US6344481B1 (en) | 2002-02-05 |
| HUP0000921A3 (en) | 2004-06-28 |
| US20020035153A1 (en) | 2002-03-21 |
| EP1036564B1 (en) | 2004-11-17 |
| US6555578B2 (en) | 2003-04-29 |
| HU0000921D0 (en) | 2000-04-28 |
| CA2299972A1 (en) | 2000-09-01 |
| HUP0000921A2 (hu) | 2000-12-28 |
| CA2299972C (en) | 2003-08-19 |
| AU1635300A (en) | 2000-09-07 |
| DE60015831D1 (de) | 2004-12-23 |
| ATE282410T1 (de) | 2004-12-15 |
| ES2233282T3 (es) | 2005-06-16 |
| KR100368354B1 (ko) | 2003-01-24 |
| JP2000256190A (ja) | 2000-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200001000B (en) | Thyromimetic antiobesity agents. | |
| HUT64512A (en) | Process for preparing acetic acid derivatives containing heteroatom with lipid level reducing activity and pharmaceutical compositions containing them | |
| HK1116766A1 (en) | 5-substituted-2-phenylamino-benzamides as mek inhibitors | |
| NO933452D0 (no) | Et terapeutisk middel for parkinson's sykdom | |
| SE9701144D0 (sv) | Novel compounds, their use and preparation | |
| DE69229442D1 (de) | Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung | |
| DE60014916D1 (de) | Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung | |
| DE69125216D1 (de) | Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen | |
| AU2342397A (en) | N-aminoalkyldibenzothiophenecarboxamides; dopamine receptor subtype specific ligands | |
| KR890011596A (ko) | 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도 | |
| DE69707372D1 (de) | Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne | |
| DE68918991D1 (de) | Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion. | |
| ATE284684T1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
| BR0317263A (pt) | Ligantes alfa2delta para o tratamento de fibromialgia e outras perturbações | |
| NZ293691A (en) | Use of a medicament containing an anilide compound for treatment of type i allergic diseases | |
| DE69518706D1 (de) | Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom | |
| DE69315363D1 (de) | Amphotere tricyclische Verbindungen als antihistaminische und antiallergische Mittel | |
| MX9703712A (es) | Derivados de 6-metoxi-1h-benzotriazol-5-carboxamida, sus procesos de produccion y las composiciones farmaceuticas que los contienen. | |
| DE69532963D1 (de) | Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen | |
| ATE81465T1 (de) | Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten. |